Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

Huntington's Disease

Alchemab Therapeutics has been awarded a grant of £1.7 million ($2 million) from Innovate UK’s Biomedical Catalyst (BMC) 2022 funding competition to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease. 

Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards first in human studies.

Alchemab is developing therapies based on naturally-derived antibodies to prevalent, hard-to-treat diseases impacting millions of people and which currently have limited therapeutic options.

Alchemab discovered the panel of antibodies through its platform and hopes that this will lead to a disease modifying therapy for Huntington’s disease. Huntington’s Disease is a devastating neurodegenerative disorder for which there is no cure or treatment to slow or stop disease progress, only treatments to help manage the symptoms.

Alchemab’s aim is to develop antibodies as therapies

Young Kwon, chief executive officer of Alchemab, said: “Our aim is to develop antibodies as therapies to transform the treatment of Huntington’s Disease by slowing or stopping the course of neurodegeneration. This latest funding from Innovate UK will enable us to accelerate development of our antibody and deliver some hope for patients.”

This is the second grant awarded to Alchemab and MDC. The financing will support preclinical development of the lead antibody to demonstrate the required safety, efficacy and manufacturability profile for first in human clinical trials and preparation for later stages of development.

Jane Osbourn, co-founder and chief scientific officer at Alchemab, said: “Alchemab’s platform flips drug discovery on its head: we start with patient response and let it guide us to the most important targets and therapeutics. I’m excited that our novel approach has led us to this potential first-in-class antibody and target. We hope that this important program is one of many, opening up a new front in our ability to combat hard-to-treat diseases such as neurodegeneration and cancers.”

MDC works to tackle industry-led challenges, overcoming the barriers that limit today’s drug discovery with effective interventions. By industrializing new technologies to better predict the probability of successful medicines discovery, connecting the life sciences ecosystem and supporting drug discovery innovators, MDC accelerates business growth, leading to improved outcomes for patients.

Innovate UK

The grant was awarded by Innovate UK, the UK’s innovation agency, as part of the Biomedical Catalyst 2022 industry-led R&D competition, to support UK businesses developing innovative health or healthcare-focussed products, technologies and processes.

Martin Main, chief scientist at MDC, said: “MDC exists to help companies like Alchemab develop innovative medicines that have the potential to change patient outcomes. We are very pleased to have secured the additional funding to continue working on this important project. By combining MDC’s expertise in pre-clinical imaging and biomarkers with Alchemab’s innovative antibody discovery platform, we hope to uncover much-needed treatment options for people living with Huntington’s Disease.”

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More